X
[{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Initiates Its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Urology","graph2":"Phase II"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Cook MyoSite","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Urology","graph2":"Phase II"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Advances Lead Candidate to Phase 2b Following FDA Type-C Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Lipella Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
LP-10 is an intravesical liposomal formulation of tacrolimus, intended for the treatment of patients suffering from moderate to severe hemorrhagic cystitis.
Lead Product(s):
Liposomal Tacrolimus
Therapeutic Area: Immunology
Product Name: LP-10
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 21, 2024
Details:
LP-410 is designed to target the underlying mechanisms of Oral Graft-Versus-Host Disease (GVHD), potentially providing a safe and effective treatment option for affected individuals.
Lead Product(s):
LP-410
Therapeutic Area: Immunology
Product Name: LP-410
Highest Development Status: IND Enabling
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 05, 2024
Details:
LP-310 is a oral rinse formulation of LP-10, which is act as Increased local concentration in oral cavity while minimalizing systemic toxicity, which is investigated for the treatment of Graft-versus-Host Disease.
Lead Product(s):
Liposomal Tacrolimus
Therapeutic Area: Immunology
Product Name: LP-310
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 10, 2023
Details:
LP-310 is a oral rinse formulation of LP-10, which is act as Increased local concentration in oral cavity while minimalizing systemic toxicity, which is investigated for the treatment of oral Lichen Planus.
Lead Product(s):
Liposomal Tacrolimus
Therapeutic Area: Immunology
Product Name: LP-310
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 20, 2023
Details:
The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.
Lead Product(s):
Tacrolimus
Therapeutic Area: Urology
Product Name: LP-10
Highest Development Status: Phase II
Product Type: Small molecule
Recipient:
Cook MyoSite
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
April 17, 2023
Details:
LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis. The product candidate is currently in Phase 2a clinical trial.
Lead Product(s):
Tacrolimus
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Product Name: LP-10
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 11, 2023
Details:
A multi-site, prospective, open-label, dose-escalation clinical trial assessing the safety and efficacy of LP-10 (liposomal tacrolimus) is now open for recruitment at several sites.
Lead Product(s):
Tacrolimus
Therapeutic Area: Urology
Product Name: LP-10
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 15, 2020